cyrilzakka/clinical-trials huggingface dataset:
Efficacy Study of Oral Collagen Peptide on Skin Condition Improvement

To assess if oral intake of collagen peptide can improve skin conditions such as skin thickness, density and firmness.

This is an one site, randomized, double-blind controlled clinical trial to assess the oral supplement of LISAVEI collagen peptide solid beverage on skin ageing improvement. Study product with collagen peptide and placebo product without collagen were randomly assigned to 90 eligible participants enrolled according to the inclusion and exclusion criteria. They took the assigned product once daily dissolved in 100 ml warm water for 12 weeks with 4-week regression phase(without intake of the test products), and visit the study site in Shanghai for four times(before starting the treatment, after 8 and 12 weeks, and 4 weeks after the last intake). Skin measurements including skin firmness, skin density, skin hydration and skin barrier were carried out at each visit with professional equipment and imaging system. Data were analyzed to validate if the administration of the test collagen peptide solid beverage will improve skin aging parameters such as firmness, thickness, density, hydration and skin barrier compared to placebo. The lasting effect was also observed by comparing between the two groups after 4-week regression time.

Eligibility Criteria:
Inclusion Criteria:

1. Healthy female adults aged between 35-55 years old
2. With fine wrinkles and skin laxity
3. Personal informed consents to participate in the study
4. Agree to keep their daily skincare routine unchanged for the duration of the study
5. Maintain good sun protection habits

5. Agree to refrain from wearing make-up on the face on the each study visit

Exclusion Criteria

1. Female who is pregnant or nursing or planning to become pregnant during the course of the study
2. Individuals who are in the perimenopausal stage.
3. BMI\<18.5 or BMI \>27.9
4. Individuals suffering from chronic systemic diseases such as cardiovascular, cerebrovascular, liver, and kidney diseases.
5. Individuals who have diabetes.
6. Individuals suffering from skin conditions such as psoriasis, eczema, atopic dermatitis, and severe acne.
7. Individuals with depression or sleep disorders, those who smoke, and those who abuse alcohol.
8. Individuals who are using hormonal drugs, medications for obesity, absorption inhibitors, antidepressants, or appetite suppressants.
9. Individuals who have used hormones or anti-inflammatory drugs on their face and upper arms within the past two months.
10. Individuals who received facial laser therapy, chemical peeling or UV overexposure in the past 3 months
11. Individuals who can not avoid prolonged exposure to sunlight.
12. Individuals who are currently participating in other clinical studies or trials.
A Long-term Evaluation of a Novel Intravaginal Device

An open-label long-term evaluation of a novel intravaginal device in female patients experiencing sexual and bladder function issues.

To determine the long-term clinical efficacy of the vSculpt therapy on treating the pelvic floor area and vaginal tissue for females who experience bladder and sexual dysfunction.

Eligibility Criteria:
Inclusion Criteria:

* All study participants are required to be biological females (genotype XX) to participate
* Female participants will be of adult age, over 18
* Female participants with self-reported concerns with bladder and sexual function
* Female participants who have reliable and consistent computer and internet access on a daily basis

Exclusion Criteria:

* Female participants shall not have an active sexually transmitted disease and/or infection
* Female participants who are actively undergoing chemotherapy or radiation
* Female participants who are currently taking any cancer-related or photosensitivity drugs
* Female participants who are pregnant, who may think they are pregnant, and/or actively trying to get pregnant during the clinical study
Optic Nerve Head Shape as a Predictor of the Formation of Acquired Pits of the Optic Nerve (APONs)

Acquired pits of the optic nerve (APONs) are an area of focal loss of neural tissue associated with a discrete area of depression/excavation within the optic cup at the level of the lamina cribrosa. It is commonly associated with glaucoma and can be seen on the optic disc when examining the back of a patient's eye. It causes a characteristic visual field defect in the central 5-10 degrees of vision which has a significant impact of a patient's daily activities. There is no treatment to restore vision once it has formed.

Previous studies suggest mechanical stress across this part of the eye may have role in the formation of APONs. The investigators therefore hypothesise that if a patient has a more elliptical shaped optic disc, which would have more irregular mechanical stress across it, it may have a higher risk of an APON forming.

Patients with glaucoma attending the ophthalmology department at University Hospital of Wales have regular photographs taken of the optic nerve/optic disc as part of their routine clinical care in order to monitor the condition. The research team, who are all practicing ophthalmologists in the department, will review anonymised photographs to find optic discs with APONs, and another group with glaucoma but no APONs to use as a control. The research team will then measure the dimensions of the optic disc to determine if APONs are more common in optic discs with a more elliptical shape. The patients' clinical notes will then need to be accessed to collect data on the age, sex and diagnosis. This data will be anonymised using ID numbers once collected.

The final outcomes of the study will the average measured dimensions of the optic disc in each group, and the position that the APON occurs.


Eligibility Criteria:
Inclusion Criteria:

* Documented diagnosis of primary open angle glaucoma (POAG) or normal tension glaucoma (NTG)
* Under the care of the ophthalmology department at University Hospital of Wales
* Available optic disc photograph
* Presence of an APON for disease group, no APON for control group

Exclusion Criteria:

* No documented diagnosis of POAG/NTG
* Other form of glaucoma - e.g. traumatic glaucoma/juvenile glaucoma
* Poor photograph quality
* Optic disc tilted so that the margin is obscured and cannot be demarcated
* Coexisting disc pathology, e.g. congenital optic disc pit
Eye Movement Desensitization and Reprocessing As a Treatment for Substance Use Disorders

Substance Use Disorders (SUD) are often comorbid with psychological trauma, however, the complex interaction between the two is not yet fully understood. Most addiction-specialized professionals do not engage in exploring past traumatic experiences of the patients due to personal, professional, and educational barriers. Therefore, psychological trauma remains highly undetected and its contribution to the development and maintenance of SUD is neglected. This compromises the therapeutic results of most interventions, with relapse rates in SUD still remaining impressively high. EMDR is one of the most effective interventions for Post-Traumatic Stress Disorder (PTSD), and has been applied to other disorders that are often comorbid with trauma, such as psychosis and depression, with promising results. Nevertheless, its application in SUD is still limited. Taken altogether, there is a need to clarify the efficacy of Eye Movement Desensitization and Reprocessing (EMDR) therapy in SUD, as well as the mechanisms of action that mediate its potential therapeutic effects.

The aim of this study is to 1) determine the efficacy of EMDR therapy in patients with SUD comorbid with psychological trauma, as well as whether changes in these clinical variables correspond to changes in salivary cortisol levels- a robust marker of the Hypothalamic-Pituitary-Adrenal (HPA) axis; 2) investigate the mechanisms of action of EMDR therapy, paying special attention to the key role that the cerebellum might play in mediating its therapeutic effects.


Eligibility Criteria:
Inclusion Criteria:

* A primary DSM-5 diagnosis of moderate to severe SUD, assessed by a clinical interview.
* No active drug consumption.
* Having experienced one or more traumatic events, assessed by the Life Event Checklist DSM-5 (LEC-5) and the Childhood Trauma Questionnaire (CTQ).
* Current posttraumatic symptoms, evaluated with the Impact Event Scale-Revised (IES-R).
* Aged from 18 to 65 years old.
* Sign an informed consent to participate in the study.
* Capable of speaking and comprehending Catalan or Spanish.

Exclusion Criteria:

* Having received a trauma-focused therapy within the last 5 years.
* Severe dissociative symptoms according to the Dissociative Experience Scale (DES).
* Presence of acute suicidal ideation.
* Acute episode of a comorbid psychiatric disorder.
* Severe cognitive impairments.
* Medical illness that compromises the HPA-axis.
* Long-term exposure to corticoids.
* Claustrophobia.
* Subjects with pacemakers.
* Presence of metallic objects within the body.
* Pregnancy
Genetic Study of Obstructive Azoospermia

In 1% of men with infertility, obstructive azoospermia (OA) may occur in congenital absence of the vas (CAVD) or idiopathic obstructive azoospermia . Many studies have shown that the pathogenic genes of OA are CFTR and ADGRG2 genes, and the inheritance mode is autosomal recessive. Although the conventional assisted reproductive technology(PESA/TESA) can help these patients have children, male patients who carry mutations of the disease-causing genes (CFTR and ADGRG2) will also pass on their mutations to the next generation, which will increase the risk of male offspring infertility. Therefore, genetic detection of CFTR and ADGRG2 genes is very necessary for CAVD patients before assisted reproduction. Genetic diagnosis plays a key role in preventing the disease to the offspring.


Eligibility Criteria:
Inclusion Criteria:

* No sperm was found after centrifugation for 15min for two or more semen tests, and the interval between two tests was at least 2 weeks.
* Blood FSH is normal;
* Hematostatin b is normal;
* Chromosome karyotype is normal or polymorphic;
* Y chromosome microdeletion did not show the deletion:(main locus);
* Biochemical fructose of seminal plasma : less than the normal value;
* PH of semen \<7.2;
* Transscrotal or transrectal ultrasound: normal testicular size(as measured by B ultrasound), presence or dysplasia of vas deferens and epididymis;

Exclusion Criteria:

* B ultrasound of urinary system suggested abnormal development;
* Transscrotal or Transrectal ultrasound indicated absence of vas deferens or epididymis or seminal vesicle;
* Physical examination showed the following abnormalities: cryptorchidism, tenderness of testis and epididymis;
* The following medical history: genitourinary tract trauma or surgical history; orchitis; epididymitis; Seminal vesicle disease; mumps;
* Laboratory examination: red and white blood cell elevation of semen routine
Magnesium and Platelet Function Testing

Magnesium has built up the reputation of a 'natural calcium antagonist'. However, the exact effect of magnesium on coagulation and more specifically on platelet function is still disputed. An important discrepancy between in vivo and in vitro studies exists. Magnesium has thus been reported to antagonize platelets in some studies, and to stimulate platelets in other studies. Current evidence seems to point in the direction of a general antagonization of aggregation and coagulation.

Intravenous magnesium is often administered in pre-eclampsia as seizure prophylaxis. Therapeutic regimens usually consist of an intravenously administered loading dose (2-3 grams) and a maintenance infusion, targeting a plasma level of 2-3 mmol/L. Therapeutic drug monitoring is needed, as magnesium toxicity is an important concern.


Eligibility Criteria:
Inclusion Criteria:

* Signed Informed consent
* Over 18 years of age (and younger or equal to 50 years of age) and able to provide legally binding consent
* American Society of Anesthesiologists physical fitness scale 1 (non smoker, no or minimal alcohol use, ..)

Exclusion Criteria:

* Chronic disease
* Chronic medical therapy (other than oral contraception)
* Pregnancy
* ASA 2 or higher
* Known coagulation or aggregation disorders
* Use of COX-inhibitors in the last 10 days
* Contra-indications for venipuncture
Probiotics in Women With Primary Dysmenorrhoea

This study compares the effect of probiotics versus placebo in women with primary dysmenorrhoea

This is a randomized controlled trial comparing probiotics against placebo in women with primary dysmenorrhoea

Eligibility Criteria:
Inclusion Criteria:

* regular menstrual cycles between 21 to 45 days
* primary dysmenorrhoea only
* willing to consume sachets twice daily for 3 months

Exclusion Criteria:

* current Intrauterine Copper Device (IUCD) user
* recent hormonal (estrogen or progesterone) therapy in last 3 months
* on treatment for allergy such as antihistamine
* diarrhoea with dairy product
* often take drugs which may affect the test results (such as medicines treating constipation or digestive medicine such as laxatives or enema)
* any malignant tumor regardless of type or site
Superficial Cervical Plexus Block for IJCL Pain Management

This is a prospective randomized trial evaluating the effect of SCPB on reported patient pain following IJCL placement as compared to local infiltrate.

The goal of this study is to determine if SCPBs provide more pain control than local infiltrate of anesthetic for internal jugular venous cannulation. The investigators hypothesis that patients who receive the SCPB will have a lower VAS rating on average than those who receive local infiltration following internal jugular venous cannulation. To test this, the investigators will be approaching eligible patients for inclusion in a research study. If the patients consent, the patients will be randomly assigned the standard of care treatment or the SCPB. The investigators will then ask the patients to rate pain following insertion of the central line. The investigators will also evaluate different aspects of the patient's hospital course to evaluate their outcomes.

Eligibility Criteria:
Inclusion Criteria:

* Patients who are 18 years and older, and;
* Present to the Akron General Emergency Department (Main) between March 1, 2021 and December 1, 2022, and;
* Require IJVC as a part of their clinical care.

Exclusion Criteria:

* Patients who are intubated; or
* Patients who undergo CPR; or
* Patients who have an allergy to lidocaine or bupivacaine; or
* Patients who have a contraindication to receiving a superficial cervical plexus block such as cellulitis over Erb's point or the internal jugular vein, abnormal anatomy, or prior surgery to the area.
The Evaluation of a Novel Nasal Mask for the Treatment of Obstructive Sleep Apnea

This investigation is a prospective, non randomized, non blinded study. This investigation is designed to evaluate the performance, comfort and ease of use with the F\&P trial nasal mask amongst Obstructive Sleep Apnea (OSA) patients.

Visit 1 will involve the participants consented in to the trial. Visit 2 will involve the participants being fitted with the F\&P trial nasal mask for use in-home.

The participant will then come in to return the mask (Visit Three) and have a final interview, this ensures the maximum time participants will be exposed to the trial mask in home will be 14 ± 4 days from visit two.

The mask will be returned to the Institution at the conclusion of the trial and the participant will return to their previous mask. The Institution will recruit all patients within 1 week of the beginning of the study.

Eligibility Criteria:
Inclusion Criteria:

* Adult (18+ years of age)
* Able to give consent
* Apnea hypopnea Index (AHI)≥ 5 on diagnostic night
* Prescribed PAP for OSA
* Existing nasal mask user

Exclusion Criteria:

* Inability to give consent
* Patients who are in a coma or a decreased level of consciousness
* Anatomical or physiological conditions making automatic positive airway pressure (APAP) therapy inappropriate (e.g. unconsolidated facial structure)
* Commercial drivers who are investigated by New Zealand Transport Agency
* Current diagnosis of carbon dioxide (CO2) retention
* Pregnant or may think they are pregnant
Automatic and Conventional Methods of Hypertensive Patients Monitoring

comparing automatic blood pressure measurments methods with conventional office methods in follow up and monitoring of hypertensive patients and predicting hypertension mediated organ damage .

Close monitoring of hypertensive patients using home and ambulatory blood pressure measurments and its role in predicting hypertention mediated organ damage. Echocardiography assessment for hypertensive patients and its important role in early detection and prevention of changes such as left ventricular hypertrophy,left atrial enlargement ,systolic and diastolic dysfunction and left ventricular mass . Microalbumiuria and early detection of renal impairment. Important role of close monitoring in management and control of hypertention and reduction of hypertensive emergencies and improvement of outcomes ,addherence to treatment , reduce of office consultation , improvement of psycosochial life ,reduce hospitalization cost and mortality rates . Digital apps has a good role in improve healthy life style and rapid detection of blood presssure changes during daily activities.

Eligibility Criteria:
Inclusion Criteria:

* Patients who were screening for suspected hypertention or white coat hypertention .
* medically underserved population .
* primary arterial hypertention .
* high risk hypertensive patients \[resistant hypertension ,patients with poor medication adherance \]

Exclusion Criteria:

* patients with secondary causes of hypertention
* patients with other cardiac diseases \[heart faliure ,valvular heart diseases \]
* chronic illness affect blood pressure as chronic kideny disease .
Combined Aerobic Exercise and Cognitive Training in Seniors With Genetic Susceptibility for Alzheimer's Disease

The study aims to investigate the effect of a long-term combined aerobic exercise and cognitive training program on cognitive function, daily function, psychosocial status, and neural plasticity in seniors with genetic susceptibility for Alzheimer's Disease.

Alzheimer's disease (AD) is the most common type of dementia and the leading cause of disability in people older than 65 years worldwide. However, there is no effective disease-modifying therapy currently. Therefore, improvement of cognitive function in people at risk and, potentially, prevention of cognitive decline has been gaining attraction.

Our previous research reported a model of a combination single nucleotide polymorphism (SNP) (rs3777215, rs234434, rs71352238, and rs4420638) can predict AD onset with high performance, which is useful to identify people at risk for AD and thus allows for timely treatment and prevention.

Both aerobic exercise and cognitive training have been demonstrated beneficial effects on cognition in subjects with AD and healthy populations. Moreover, the synergistic effects of the combination have been proven recently. However, the effect of combined aerobic exercise and cognitive training on seniors with genetic susceptibility for AD remains to be elucidated. Herein, this study aims to

1. assess the effects of long-term combined aerobic exercise and cognitive training on cognitive function, daily function, psychosocial status, and neural plasticity in seniors with single nucleotide polymorphism of rs3777215, rs234434, rs71352238, and rs4420638.
2. confirm the predictive value of the SNP model for AD in a longitudinal setting.

Eligibility Criteria:
Inclusion Criteria:

* Mandarin-speaking subjects.
* Not clinically demented.
* Meeting the cutoff values of MMSE and CDR.
* With positive variation of rs3777215, rs234434, rs71352238, and rs4420638.

Exclusion Criteria:

* Had major neurologic diagnosis (e.g., Parkinson's disease, stroke, encephalitis, and epilepsy) or other condition that might impair cognition or confound assessments.
* Had a history of psychotic episodes or had major depression (Hamilton Depression Rating Scale score \> 24 points).
* Had severe systemic diseases, such as tumors, cardiovascular or orthopedic disorder that can affect the ability to perform the proposed intervention tasks.
Effects of TENS and Mindfulness Meditation in Persons With HIV-related Neuropathy

This study is to explore the effects of transcutaneous nerve stimulation (TENS) and mindfulness meditation in persons living with HIV (PLHIV) and painful neuropathy in the feet.

The overall goal of this study is to conduct an interventional pilot trial of mindfulness meditation and transcutaneous nerve stimulation (TENS) to mitigate the symptoms and improved function in persons living with HIV (PLHIV) and painful neuropathy in the feet. .

The investigators aim to determine the feasibility and effects of (1) mindfulness meditation or (2) transcutaneous nerve stimulation (TENS) on clinical and functional outcomes in participants with HIV-associated painful distal sensory polyneuropathy in the feet. This aim will be achieved with a randomized control pilot trial with 3 groups: TENS group, Mindfulness Mediation Group, and Usual Treatment (Control) group. The interventions will be performed at home over a period of 6 weeks.

Eligibility Criteria:
Inclusion Criteria:

* diagnosis of HIV infection currently treated with antiretroviral therapy (ART)
* cluster of differentiation 4 cell (CD4 cell) count of at least 200 cells/mm3
* 18-64 years of age
* able to read and write in English
* means to travel to a study site
* presence of peripheral neuropathy symptoms in feet
* average daily self-reported pain in the feet of at least 3/10 on a 0-10 numerical pain scale
* pain in the feet present for at least the past 3 months
* no changes in medications used to manage pain in the past 4 weeks
* no use of TENS or mindfulness meditation in the prior 6 months
* availability of a mobile phone to receive text messages over the course of the intervention period

Exclusion Criteria:

* current opportunistic infection(s)
* cluster of differentiation 4 cell (CD4 cell) count \<200 cells/mm3
* dementia
* uncontrolled psychiatric disorder
* wounds or sores on the feet
* musculoskeletal or neurological conditions (other than distal sensory neuropathy) that may affect gait
* pregnancy